Navigation Links
WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference
Date:9/3/2009

FREMONT, Calif., Sept. 3 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that Mr. Alnoor Shivji, President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held September 9-11, 2009, at the New York Palace Hotel in New York.

Mr. Shivji's presentation will take place at 4:30 p.m. on Thursday, September 10th in the Fahnestock Salon. The presentation will include an overview of the company's SmartChip(TM) system, which has undergone successful alpha testing at The University of Pittsburg Medical Center (UPMC). As a result of the positive data, WaferGen has initiated multiple collaborations with academic research centers in the US and Europe. A live webcast of the presentation will be available at www.wafergen.com and will be archived for 90 days.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.

Forward-Looking Statements

This press release may contain certain "forward-looking statements". Such statements include statements relating to the recent strengthening of the leadership team of the company and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Contact:
    Michelle Schonemann
    510-360-6111
    michelle.schonemann@wafergen.com


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
7. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
8. WaferGen Announces Signing of Two Private Placements
9. WaferGen to Present at the Ninth Annual Beyond Genome Conference
10. WaferGen Announces Second Quarter 2008 Financial Results
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading ... today announced that it has been named to The Silicon Review’s “20 Fastest Growing ... other markets, Cambridge Semantics serves the needs of end users facing some of the ...
(Date:4/27/2016)... SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today ... Executive Officer, of United Therapeutics will provide an overview ... Bank 41 st Annual Health Care Conference. ... 5, 2016, at 10:00 a.m. Eastern Time, and can ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. ... Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from the ... the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , the ... the company as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial ... was most recently Chief Commercial Officer of Pathway Genomics. He has held senior ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):